Thelansis

Relapsed or Refractory Follicular Lymphoma (r/r FL) Market Outlook Thelansis’s “Relapsed or Refractory Follicular Lymphoma (r/r FL) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Relapsed or Refractory Follicular Lymphoma (r/r FL) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Relapsed or Refractory Follicular Lymphoma (r/r FL) Overview Relapsed or Refractory Follicular Lymphoma is an indolent B-cell non-Hodgkin lymphoma driven by BCL2 overexpression and clonal evolution, persisting or recurring after prior therapy. It presents with painless lymphadenopathy, fatigue, and constitutional symptoms; histologic transformation...

HER2-Positive Metastatic Breast Cancer Emerging Therapy and TPP Insights Thelansis’s “HER2-Positive Metastatic Breast Cancer Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . HER2-Positive Metastatic Breast Cancer Overview HER2-positive metastatic breast cancer is a highly aggressive molecular subtype driven by ERBB2 gene amplification, resulting in marked HER2 transmembrane tyrosine kinase overexpression and constitutive pro-survival signalling. Characterised by rapid disease progression, frequent visceral involvement, and significant central nervous system metastasis predilection, its natural history has been fundamentally transformed by targeted precision medicine. Rigorous HER2 status validation via immunohistochemistry...

Autism Spectrum Disorder (ASD) Emerging Therapy and TPP Insights Thelansis’s “Autism Spectrum Disorder (ASD) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Autism Spectrum Disorder (ASD) Overview Autism spectrum disorder (ASD) is a complex, highly heterogeneous neurodevelopmental condition clinically defined by two core diagnostic domains: persistent deficits in social communication and reciprocal interaction across multiple contexts, alongside the presence of restricted, repetitive patterns of behavior, interests, or activities. While the etiology is multifactorial—strongly linked to high heritability, advanced parental age, extreme prematurity, and specific genetic syndromes like Fragile X—the phenotypic expression var...

Metastatic Colorectal Cancer Emerging Therapy and TPP Insights Thelansis’s “Metastatic Colorectal Cancer Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Metastatic Colorectal Cancer Overview Metastatic colorectal cancer is the advanced disseminated stage of colorectal cancer, with liver, lung, and peritoneum representing the most frequent metastatic sites, driven by accumulated somatic mutations in APC, KRAS, NRAS, BRAF V600E, and PIK3CA alongside mismatch repair status profoundly influencing therapeutic selection and prognosis. Comprehensive molecular profiling encompassing RAS and BRAF mutation status, mismatch repair and MSI testing, HER2 amplification, and NTRK fusion analysis is mandatory at diagnosis. Patients present with p...

Alport Syndrome Emerging Therapy and TPP Insights Thelansis’s “Alport Syndrome Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Alport Syndrome Overview Alport Syndrome is a hereditary nephropathy caused by COL4A3, COL4A4, or COL4A5 mutations disrupting type IV collagen, leading to glomerular basement membrane instability, progressive nephron loss, and sensorineural hearing impairment. It presents with microscopic hematuria, proteinuria, declining eGFR, and bilateral high-frequency hearing loss. Diagnosis combines electron microscopy showing GBM lamellation with genetic confirmation; proteinuria burden and eGFR trajectory reflect severity. Early RAS blockade combined with SGLT2 inhibitors forms the dual nephroprotective st...

Asthma Emerging Therapy and TPP Insights Thelansis’s “Asthma Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Asthma Overview Asthma is a chronic inflammatory airway disease characterised by variable, reversible airflow obstruction, bronchial hyperresponsiveness, and airway remodelling, driven predominantly by Th2-mediated eosinophilic inflammation — with type 2 cytokines IL-4, IL-5, and IL-13 central to its pathobiology — alongside non-eosinophilic neutrophilic and mixed phenotypes recognising asthma’s considerable biological heterogeneity. Genetic susceptibility, allergen sensitisation, respiratory viral infections, occupational exposures, and obesity interact as key disease determinants. Patients present with episodic wheeze, dyspnoea...